Annual CCF Conference Brings Together All Stakeholders

June 2023, Vol 4, No 2
Milind M. Javle, MD
Hubert L. and Olive Stringer Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
M.D. Anderson Cancer Center
Houston, TX
Chair, NCI Task Force: Hepatobiliary Cancers

This issue of CCA News highlights the Cholangiocarcinoma Foundation (CCF) 10th Annual Conference held in April. This meeting was chaired by Dr Chiara Branconi, a Lord Kelvin Adam Smith Reader at the University of Glasgow and a medical oncologist with Beatson Cancer Centre; and Dr Laura Goff, medical director of the Vanderbilt-Ingram Cancer Center’s Hematology and Oncology Division. The focus was on emerging research and new, innovative therapies that improve patient outcomes. One of the unique aspects of these conferences has been the time investigators and clinicians can spend with patients and advocates, along with scientists and other providers. A highlight of this year’s conference was the announcement of the foundation’s first Chief Medical Officer, Juan Valle, MD, MB ChB, MSc. Dr Valle is a well-known clinician and researcher known for his work in biliary cancer worldwide. He begins his new position in August 2023.

This conference recapped the latest research in cholangiocarcinoma and quality-of-life issues, such as nutritional support. Stephanie Roit, a nutrition specialist, reviewed the current data and brought forth her own personal experiences. She recommended protein from various sources along with fruits and vegetables as tolerated while limiting the intake of ultra-processed foods. She also discussed the ketogenic diet, which is a high-fat, low-fiber diet with antioxidants that currently lacks clinical trial data in these patients. Dr Tim Greten described novel targets and therapies beyond chemotherapy, including agents targeting cancer-associated fibroblasts, agents targeting metabolic programing, and immunologic interventions beyond checkpoint inhibitors, including chimeric antigen receptor T cells, bispecific antibodies, agonistic checkpoint antibodies, and innovative combination strategies.

Drs Gordon Moffatt and Jennifer Knox from Princess Margaret Cancer Center, Toronto, have recently presented an insightful review of hepatocholangiocarcinoma, an uncommon disease that represents a composite of both cancer types. As they describe, this disease has genomic characteristics of both cancers, and current treatment standards are based on limited retrospective data. We hope that prospective studies of this cancer will change the treatment paradigm and offer clinical benefit as noted recently in hepatocellular cancer and cholangiocarcinoma.

Finally, I would like to conclude by quoting a caregiver who attended the conference this year: “I lost my father to this disease and certainly did not want anyone else to lose their loved ones to it,” said CCF volunteer Ambuj Srivastava. “Getting the chance to play a role in helping improve treatments for future patients means a lot to me and my father’s legacy. I’m grateful for the deep collaboration between experts, patients, and caregivers.”


Milind M. Javle, MD

Related Items

Annual CCA Summit Is Now a Key Scientific Meeting in BTCs
By Milind M. Javle, MD
December 2023, Vol 4, No 4
The 5th annual CCA Summit, held October 19-21, 2023, in Scottsdale, AZ, was a very successful meeting by all measures and has gradually become one of the key scientific meetings in biliary tract cancers.
Advances in the Management of Patients With Biliary Cancer
By Milind M. Javle, MD
September 2023, Vol 4, No 3
As we approach the fall season, it is wonderful to reflect on some of the amazing research presented this year, most recently at the ASCO 2023 annual meeting. One of the major highlights of ASCO this year included the results of HER2/neu-directed novel therapies in biliary cancer. Shubham Pant, MD, MBBS, from MD Anderson Cancer Center, presented the results of the HERIZON-1 clinical trial of the bispecific antibody zanidatamab in HER2/neu-expressing biliary cancers.
Exciting New Abstracts from the ASCO GI Cancers Symposium
By Milind M. Javle, MD
March 2023, Vol 4, No 1
Dr Javle provides his perspective on important abstracts presented at the ASCO Gastrointestinal Cancers Symposium, held January 19-21, 2023, in San Francisco, CA.
Highlights from the Fourth Annual CCA Summit
By Milind M. Javle, MD
December 2022, Vol 3, No 4
We have recently concluded the 4th Annual CCA Summit, which was held on October 13-15, 2022, in Denver, Colorado.
New Standard of Care Emerging for Treatment of BTCs
By Milind M. Javle, MD
September 2022, Vol 3, No 3
On September 2, 2022, the US Food and Drug Administration approved durvalumab in combination with gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) on the basis of the TOPAZ-1 study.
Rapid Trajectory of Clinical Research in Biliary Tract Cancers
By Milind M. Javle, MD
March 2022, Vol 3, No 1
The 2022 ASCO GI Cancers Symposium clearly highlighted the rapid trajectory of clinical research in biliary tract cancers. One of the most eagerly anticipated studies, TOPAZ-1, was presented by Do-Youn Oh, MD, PhD, from Seoul National University Hospital in South Korea. This phase 3 clinical trial enrolled 685 patients and investigated the addition of the PD-L1–directed agent durvalu­mab to gemcitabine and cisplatin chemotherapy backbone versus these chemotherapies alone. The results demonstrated a statistically significant improvement in overall survival (OS), overall response rate (ORR), and progression-free survival (PFS), without dose-limiting toxicities.
Hot Topics at ASCO-GI 2022
By Milind M. Javle, MD
Dr Milind Javle provides his perspectives on key presentations on cholangiocarcinoma and biliary tract cancer at the 2022 ASCO Gastrointestinal Cancers Symposium.
Cholangiocarcinoma Research Continues to Thrive
By Milind M. Javle, MD
December 2021, Vol 2, No 4
The Third CCA Summit was held on October 21-22, 2021 in New Orleans. For the majority of the cholangiocarcinoma (CCA) community, this was their first “live” meeting since the pandemic.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: